ChiCTR2300074995 版本V1.1 版本创建时间2024/01/18 11:42:46 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300074995 

最近更新日期:

Date of Last Refreshed on:

2023-08-22 16:27:40 

注册时间:

Date of Registration:

2023-08-22 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

床旁超声测量胃窦横截面积评估大承气汤治疗脓毒症胃肠功能障碍的临床研究

Public title:

Clinical Study of dachengqi decoction in the treatment of sepsis complication with gastrointestinal dysfunction via gastric antrum cross-sectional area measured by bedside ultrasound

注册题目简写:

English Acronym:

研究课题的正式科学名称:

床旁超声测量胃窦横截面积评估大承气汤治疗脓毒症胃肠功能障碍的临床研究

Scientific title:

Clinical Study of dachengqi decoction in the treatment of sepsis complication with gastrointestinal dysfunction via gastric antrum cross-sectional area measured by bedside ultrasound

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李探 

研究负责人:

邵龙刚 

Applicant:

Li Tan 

Study leader:

Shao Longgang 

申请注册联系人电话:

Applicant telephone:

+86 187 6142 5028

研究负责人电话:

Study leader's
telephone:

+86 139 1393 9943

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1006908001@qq.com

研究负责人电子邮件:

Study leader's E-mail:

shaolonggang@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

南京市建邺区南湖路23号

研究负责人通讯地址:

南京市建邺区南湖路23号

Applicant address:

No.23, Nanhu Road, Jianye District, Nanjing City

Study leader's address:

No.23, Nanhu Road, Jianye District, Nanjing City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省第二中医院

Applicant's institution:

The Second Chinese Medicine Hospital of Jiangsu Province

研究负责人所在单位:

江苏省第二中医院

Affiliation of the Leader:

The Second Chinese Medicine Hospital of Jiangsu Province

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022SEZ-012-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江苏省第二中医院伦理委员会

Name of the ethic committee:

Ethics Committee of The Second Chinese Medicine Hospital of Jiangsu Province

伦理委员会批准日期:

Date of approved by ethic committee:

2022-05-31 00:00:00

伦理委员会联系人:

张建斌

Contact Name of the ethic committee:

zhangjianbin

伦理委员会联系地址:

南京市建邺区南湖路23号

Contact Address of the ethic committee:

No.23, Nanhu Road, Jianye District, Nanjing City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 25 8923 1036

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省第二中医院

Primary sponsor:

The Second Chinese Medicine Hospital of Jiangsu Province

研究实施负责(组长)单位地址:

南京市建邺区南湖路23号

Primary sponsor's address:

No.23, Nanhu Road, Jianye District, Nanjing City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省第二中医院

具体地址:

江苏省南京市建邺区南湖路23号

Institution
hospital:

The Second Chinese Medicine Hospital of Jiangsu Province

Address:

No.23, Nanhu Road, Jianye District, Nanjing City, Jiangsu Province

经费或物资来源:

江苏省中医药管理局

Source(s) of funding:

Jiangsu Provincial Administration of Traditional Chinese Medicine

研究疾病:

脓毒症胃肠功能障碍  

Target disease:

sepsis complication with gastrointestinal dysfunction

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

应用床旁超声测量胃窦横截面积(CSA)来评估大承气汤治疗脓毒症胃肠功能障碍的临床价值  

Objectives of Study:

To evaluate the clinical value of dachengqi decoction in the treatment of sepsis complication with gastrointestinal dysfunction via gastric antrum cross-sectional area measured by bedside ultrasound.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

符合脓毒症胃肠功能障碍诊断标准;年龄18~89岁;接受鼻饲置管者;患者本人自愿或授权者家属知情同意并签署同意书。

Inclusion criteria

Meet the diagnostic criteria for gastrointestinal dysfunction in sepsis; age 18 to 89 years old; receive nasal feeding tube; give informed consent from the patient or the patient family.

排除标准:

曾接受食管、胃及胰十二指肠手术者;入院时合并有严重消化道出血不能给予肠内喂养者;明确病理学诊断为胃肠道恶性肿瘤;小肠喂养者;治疗未达到7 d死亡或自动出院者。

Exclusion criteria:

Patients who had undergone esophageal, stomach and pancreaticoduodenal surgery; patients who are admitted with severe gastrointestinal bleeding and cannot receive enteral feeding; definite pathological diagnosis of gastrointestinal malignancy; small bowel feeding; treatment without 7 d death or automatic discharge.

研究实施时间:

Study execute time:

From 2021-11-01 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-06-01 00:00:00 To 2024-05-31 00:00:00

干预措施:

Interventions:

组别:

大承气汤组(观察组)

样本量:

40

Group:

Dachengqi decoction group (observation group)

Sample size:

干预措施:

大承气汤组(观察组)患者给予西医常规治疗,具体参照2021年脓毒症及脓毒症休克管理国际指南,采用包括针对脓毒症患者常规的液体复苏、抗感染、血管活性药物、维持内环境平衡、营养支持、机械通气等治疗措施,并给予早期滋养型喂养、促进胃肠道动力、调节肠道菌群等处理。 另外在西医治疗的基础上联合大承气汤口服治疗。大承气汤药物组成:大黄(12克)、厚朴(24克)、枳实(12克)、芒硝(6克),采用煎药机煎制成浓煎剂(30 mL),早晚分次口服,疗程为7d。

干预措施代码:

Intervention:

The dachengqi decoction group (observation group) is given western medicine conventional treatment, specific reference to the 2021 sepsis and septic shock management international guidelines, including for sepsis patients routine fluid resuscitation, anti-infection, vasoactive drugs, maintain the environment balance, nutritional support, mechanical ventilation, treatment measures, and give early nourishing feeding, promote gastrointestinal motility, regulating the intestinal flora treatment. The observation group combined oral treatment on the basis of western medicine treatment. Drug composition: rhubarb (12 grams), magnolia officinalis (24 grams), bitter orange (12 grams), awn nitrate (6 grams), decocted by decocting machine (30 ml), taken orally in the morning and evening, the course of patients was 7d.

Intervention code:

组别:

常规治疗组(对照组)

样本量:

40

Group:

Conventional treatment group (control group)

Sample size:

干预措施:

常规治疗组(对照组)患者给予西医常规治疗,具体参照2021年脓毒症及脓毒症休克管理国际指南,采用包括针对脓毒症患者常规的液体复苏、抗感染、血管活性药物、维持内环境平衡、营养支持、机械通气等治疗措施,并给予早期滋养型喂养、促进胃肠道动力、调节肠道菌群等处理。

干预措施代码:

Intervention:

The conventional treatment group (control group) is given western medicine conventional treatment, specific reference to the 2021 sepsis and septic shock management international guidelines, including for sepsis patients routine fluid resuscitation, anti-infection, vasoactive drugs, maintain the environment balance, nutritional support, mechanical ventilation, treatment measures, and give early nourishing feeding, promote gastrointestinal motility, regulating the intestinal flora treatment.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

jiangsu

City:

单位(医院):

江苏省第二中医院 

单位级别:

三甲 

Institution
hospital:

The Second Chinese Medicine Hospital of Jiangsu Province

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

胃窦横截面积

指标类型:

主要指标

Outcome:

Gastric antrum cross-sectional area

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃肠功能障碍评分

指标类型:

次要指标

Outcome:

Gastrointestinal dysfunction score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性生理学与慢性健康状况评分Ⅱ

指标类型:

次要指标

Outcome:

APACHEⅡ

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清前蛋白(PA)、白蛋白(Alb)

指标类型:

次要指标

Outcome:

Serum preprotein (PA), albumin (Alb)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血清

组织:

Sample Name:

Serum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 89 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

利用物理方法在计算机上产生随机数

Randomization Procedure (please state who generates the random number sequence and by what method):

Using physical methods to generate random numbers on a computer

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

采用网络平台:临床试验公共管理平台 Clinical Trial Management Public Platform(http://www.medresman.org),实验结题后公布

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Clinical Trial Management Public Platform(http://www.medresman.org)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理一部分为:病例记录表(Case Record Form, CRF),另一部分使用ResMan电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data acquisition and management part is: case records form (Case Record Form, CRF), another part uses the resman electronic acquisition and management system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-08-22 16:27:35